🟢 Telix Pharmaceuticals is trading 10% up today after FDA approves Pixclara for glioma

Telix Pharmaceuticals is trading 10.10% up now at A$17.99 after the U.S. FDA approved Pixclara on September 14, 2026.

• Pixclara is the first FDA-approved FET-PET imaging drug for glioma.
• It helps distinguish recurrent or progressive brain tumors from treatment-related changes in adults and children.
• The approval addresses a significant unmet medical need and provides a major regulatory and commercial catalyst.